Clinical Trials Browser

INDUSTRY × HER2-positive Breast Cancer × Capecitabine × Clear all

NCT07413939 2026-05-11

BREnnA

Phase 2/3 Recruiting

HER2-positive Breast Cancer

NCT04220203 2025-06-26

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Approved for marketing

HER2-positive Breast Cancer